KDA
- Current
- Browse
- Collections
-
For contributors
- For Authors
- Instructions for authors
- Article processing charge
- For Reviewers
- Instructions for reviewers
- How to become a reviewer
- Best reviewers
- For Readers
- Readership
- Subscription
- Permission guidelines
- About
- Editorial policy
Search
- Page Path
- HOME > Search
Original Article
- Complications
- Associations of Plasma Glucagon Levels with Estimated Glomerular Filtration Rate, Albuminuria and Diabetic Kidney Disease in Patients with Type 2 Diabetes Mellitus
- Hua-Xing Huang, Liang-Lan Shen, Hai-Yan Huang, Li-Hua Zhao, Feng Xu, Dong-Mei Zhang, Xiu-Lin Zhang, Tong Chen, Xue-Qin Wang, Yan Xie, Jian-Bin Su
- Diabetes Metab J. 2021;45(6):868-879. Published online March 23, 2021
- DOI: https://doi.org/10.4093/dmj.2020.0149
- 9,659 View
- 193 Download
- 8 Web of Science
- 8 Crossref
-
Abstract
PDF
Supplementary Material
PubReader 
ePub - Background
Type 2 diabetes mellitus (T2DM) is characterized by elevated fasting glucagon and impaired suppression of postprandial glucagon secretion, which may participate in diabetic complications. Therefore, we investigated the associations of plasma glucagon with estimated glomerular filtration rate (eGFR), albuminuria and diabetic kidney disease (DKD) in T2DM patients.
Methods
Fasting glucagon and postchallenge glucagon (assessed by area under the glucagon curve [AUCgla]) levels were determined during oral glucose tolerance tests. Patients with an eGFR <60 mL/min/1.73 m2 and/or a urinary albumin-to-creatinine ratio (UACR) ≥30 mg/g who presented with diabetic retinopathy were identified as having DKD.
Results
Of the 2,436 recruited patients, fasting glucagon was correlated with eGFR and UACR (r=–0.112 and r=0.157, respectively; P<0.001), and AUCgla was also correlated with eGFR and UACR (r=–0.267 and r=0.234, respectively; P<0.001). Moreover, 31.7% (n=771) presented with DKD; the prevalence of DKD was 27.3%, 27.6%, 32.5%, and 39.2% in the first (Q1), second (Q2), third (Q3), and fourth quartile (Q4) of fasting glucagon, respectively; and the corresponding prevalence for AUCgla was 25.9%, 22.7%, 33.7%, and 44.4%, respectively. Furthermore, after adjusting for other clinical covariates, the adjusted odds ratios (ORs; 95% confidence intervals) for DKD in Q2, Q3, and Q4 versus Q1 of fasting glucagon were 0.946 (0.697 to 1.284), 1.209 (0.895 to 1.634), and 1.521 (1.129 to 2.049), respectively; the corresponding ORs of AUCgla were 0.825 (0.611 to 1.114), 1.323 (0.989 to 1.769), and 2.066 (1.546 to 2.760), respectively. Additionally, when we restricted our analysis in patients with glycosylated hemoglobin <7.0% (n=471), we found fasting glucagon and AUCgla were still independently associated with DKD.
Conclusion
Both increased fasting and postchallenge glucagon levels were independently associated with DKD in T2DM patients. -
Citations
Citations to this article as recorded by
- Acetylation of CPT1A reduces fatty acid oxidation and leads to dysfunctional renal tubular mitochondria in diabetic kidney disease
Siyao Sun, Sen Liu, Shiyan Ruan, Hongli Zhou, Xiangfei Cui, Ning Lu, Liu Hong, Miaomiao Lu
Biochemical Pharmacology.2026; 243: 117465. CrossRef - The novel antidiabetic medications on diabetic retinopathy: relevant molecular mechanisms, advancing diagnostic innovations, and therapeutic implications
Song Wen, Chenglin Xu, Yue Yuan, Lijiao Chen, Yishu Ren, Zhimin Xu, Jianlan Jin, Jiyu Li, Ligang Zhou
Frontiers in Medicine.2026;[Epub] CrossRef - Glucagon in metabolic disease: a mini-review of emerging multi-organ roles beyond glycemic control
Seung Hee Lee, Hyeon Young Park, Ji Ho Yun, Eun Kyoung Do
Frontiers in Endocrinology.2025;[Epub] CrossRef - Prolonged glucagon exposure rewires lipid oxidation and drives diabetic kidney disease progression
Xingfeng Liu, Jingwen Chen, Shengying Gu, Yibing Chen, Ruiping Zhang, Qingce Zang, Ting Li, Hanwen Li, Dejin Lu, Shaocong Hou, Lijuan Kong, Qian Jiang, Caiyi Xing, Wenjia Fan, Yanjun Wan, Jiaqi Zhang, Linyuan Zhu, Chunxiao Ma, Qijin Zhao, Hai Yan, Zeper A
Nature Communications.2025;[Epub] CrossRef - Fasting glucagon as an independent risk indicator for CAD in patient with type 2 diabetes
Linlin Kong, Lina Chang, Jiamin Nie, Yian Gu, Xin Wang, Siyu Yan, Wantong Han, Hequn Sang, Shaofang Tang, Ming Liu, Qing He
Frontiers in Endocrinology.2025;[Epub] CrossRef - Random survival forest for predicting the combined effects of multiple physiological risk factors on all-cause mortality
Bu Zhao, Vy Kim Nguyen, Ming Xu, Justin A. Colacino, Olivier Jolliet
Scientific Reports.2024;[Epub] CrossRef - Endocrine Disorders in Nephrotic Syndrome—A Comprehensive Review
Maja Mizdrak, Bozo Smajic, Ivan Mizdrak, Tina Ticinovic Kurir, Marko Kumric, Ivan Paladin, Darko Batistic, Josko Bozic
Biomedicines.2024; 12(8): 1860. CrossRef - Glucagon in type 2 diabetes: Friend or foe?
Irene Caruso, Nicola Marrano, Giuseppina Biondi, Valentina Annamaria Genchi, Rossella D'Oria, Gian Pio Sorice, Sebastio Perrini, Angelo Cignarelli, Annalisa Natalicchio, Luigi Laviola, Francesco Giorgino
Diabetes/Metabolism Research and Reviews.2023;[Epub] CrossRef
- Acetylation of CPT1A reduces fatty acid oxidation and leads to dysfunctional renal tubular mitochondria in diabetic kidney disease
First
Prev
